ClinicalTrials.gg
RecruitingNCT07941063Updated Nov 17, 2026

Multimodal Ultrasound for Lymphoma Classification and Treatment Response Prediction

An observational study in Lymphoma, Hodgkin Lymphoma and Non-Hodgkin Lymphoma, sponsored by Chinese PLA General Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Chinese PLA General Hospital · Observational

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.
Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Lymphoma by Chinese PLA General Hospital — 7 open to participants now, 7 under way, none of them phase 3. Lymphoma · Chinese PLA General Hospital.

Started
2026
with 1 other
Observational
2 of 11
1 open now
Registered
11th of 11
by date

Among the 11 studies in Lymphoma by Chinese PLA General Hospital, this one is one of 2 that started in 2026, is one of 2 observational ones, and was the 11th registered.

Lymphoma

3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.

Browse Lymphoma studies →

Open to participants now

7 of the 11 studies in Lymphoma by Chinese PLA General Hospital are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Lymphoma by Chinese PLA General Hospital, or all of them as a file.
02

Study summary

This prospective, multicenter, observational cohort study aims to evaluate whether multimodal ultrasound can support the noninvasive classification of lymphoma and the early prediction of treatment response.

Adults with newly diagnosed and previously untreated lymphoma will undergo standardized multimodal ultrasound examinations before treatment, after the first treatment cycle, after the fourth treatment cycle, and during follow-up. Ultrasound examinations will include B-mode ultrasound, color Doppler flow imaging, contrast-enhanced ultrasound, super-resolution contrast-enhanced ultrasound, and ultrasound viscoelasticity imaging. Clinical, laboratory, pathological, molecular, treatment, and follow-up information will also be collected.

The study will investigate differences in ultrasound characteristics among lymphoma subtypes, evaluate changes in ultrasound features during treatment, and develop and validate prediction models integrating imaging and clinical information. The main hypothesis is that multimodal ultrasound features and their early treatment-related changes reflect the biological heterogeneity of lymphoma and can improve noninvasive lymphoma classification and early prediction of treatment response.

Read the detailed description

This is a prospective, multicenter, observational cohort study of adults with newly diagnosed, previously untreated lymphoma. The study plans to prospectively enroll approximately 2,000 participants across participating centers.

Standardized multimodal ultrasound data will be collected at predefined time points, including before treatment, after the first treatment cycle, after the fourth treatment cycle, and during subsequent follow-up. Imaging modalities include B-mode ultrasound (BUS), color Doppler flow imaging (CDFI), contrast-enhanced ultrasound (CEUS), super-resolution contrast-enhanced ultrasound (SR-CEUS), and ultrasound viscoelasticity imaging (UVE). Clinical and laboratory information, treatment information, pathological diagnosis, immunohistochemical findings, molecular and genetic test results, and follow-up information will also be collected.

The study will first characterize multimodal ultrasound phenotypes across lymphoma categories, including Hodgkin lymphoma and non-Hodgkin lymphoma, indolent and aggressive non-Hodgkin lymphoma, and common pathological subtypes. Longitudinal changes in ultrasound features during treatment will then be evaluated to identify imaging characteristics associated with treatment response.

Using the collected multimodal imaging and clinical data, statistical and machine-learning approaches will be used to develop and validate models for lymphoma classification and early treatment-response prediction. Model development will incorporate imaging features from multiple ultrasound modalities together with relevant clinical information. Model performance will be evaluated using measures of discrimination, calibration, and clinical utility, as appropriate.

The overall objective is to determine whether multimodal ultrasound can provide a noninvasive and repeatable approach for characterizing lymphoma heterogeneity and for identifying treatment response at an earlier stage of therapy.

03

Conditions studied

  • Lymphoma
  • Hodgkin Lymphoma
  • Non-Hodgkin Lymphoma

Keywords

  • Multimodal Ultrasound
  • Super-Resolution Contrast-Enhanced Ultrasound
  • Ultrasound Viscoelasticity
  • Treatment Response
  • Lymphoma Classification
  • Contrast-Enhanced Ultrasound
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults with histopathologically confirmed, newly diagnosed, previously untreated lymphoma who present to participating study centers and have at least one lesion suitable for standardized multimodal ultrasound evaluation will be prospectively enrolled.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 years or older.
  2. Histopathologically confirmed lymphoma.
  3. Newly diagnosed and previously untreated, with no prior radiotherapy, chemotherapy, targeted therapy, immunotherapy, or other systemic antitumor treatment before enrollment.
  4. At least one superficial or otherwise accessible lesion that can be clearly evaluated by ultrasound, such as a cervical, axillary, or inguinal lymph node, with an adequate acoustic window allowing stable acquisition of all five ultrasound modalities.
  5. Expected survival of more than 3 months.
  6. No to the use of ultrasound contrast agents.
  7. Willingness to undergo multimodal ultrasound examinations before, during, and after treatment and provision of written .

Exclusion criteria

Exclusion Criteria:

  1. Target lesion located too deeply or obscured by gas or bone, preventing acquisition of a stable ultrasound imaging plane.
  2. Known history of to any component of the ultrasound contrast agent (sulfur hexafluoride microbubbles).
  3. Known right-to-left cardiac shunt, severe pulmonary hypertension with pulmonary artery pressure greater than 90 mmHg, or uncontrolled hypertension.
  4. Acute respiratory distress syndrome or severe respiratory insufficiency.
  5. Unstable angina or acute myocardial infarction within the previous 1 week.
  6. Pregnancy or breastfeeding.
  7. Inability, in the investigator's judgment, to cooperate with the complete examination procedure or complete the required follow-up.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Newly Diagnosed Untreated Lymphoma Cohort

    Adults with pathologically confirmed, newly diagnosed, previously untreated lymphoma who undergo longitudinal multimodal ultrasound examinations and clinical follow-up according to the study protocol.

    Diagnostic Test: Multimodal Ultrasound Examination

Interventions

  • Diagnostic testMultimodal Ultrasound Examination

    Participants undergo standardized multimodal ultrasound examinations including B-mode ultrasound (BUS), color Doppler flow imaging (CDFI), contrast-enhanced ultrasound (CEUS), super-resolution contrast-enhanced ultrasound (SR-CEUS), and ultrasound viscoelasticity imaging (UVE). Examinations are performed at predefined study time points, including before treatment, after the first treatment cycle, after the fourth treatment cycle, and during follow-up. The imaging findings are collected for lymphoma classification and treatment-response prediction.

06

What researchers measure

Primary outcomes

  1. Area Under the Receiver Operating Characteristic Curve for Differentiating Hodgkin Lymphoma From Non-Hodgkin Lymphoma

    The area under the receiver operating characteristic curve (AUC) of the multimodal ultrasound model for distinguishing Hodgkin lymphoma from non-Hodgkin lymphoma, using histopathological diagnosis as the reference standard.

    Time frame: At the pretreatment baseline assessment, before initiation of antitumor treatment.

  2. Area Under the Receiver Operating Characteristic Curve for Differentiating Indolent From Aggressive Non-Hodgkin Lymphoma

    The area under the receiver operating characteristic curve (AUC) of the multimodal ultrasound model for distinguishing indolent from aggressive non-Hodgkin lymphoma, using histopathological classification as the reference standard.

    Time frame: At the pretreatment baseline assessment, before initiation of antitumor treatment.

  3. Area Under the Receiver Operating Characteristic Curve for Predicting Complete Response After the Fourth Treatment Cycle Using First-Cycle Multimodal Ultrasound

    The area under the receiver operating characteristic curve (AUC) will be used to evaluate the ability of the multimodal ultrasound model to predict complete response (CR) after completion of Cycle 4, using ultrasound features obtained after completion of Cycle 1. Complete response will be assessed by PET/CT or CT according to the study protocol. Each treatment cycle is scheduled to last 21 or 28 days, depending on the prescribed first-line regimen. Assessments are linked to completion of the relevant treatment cycle; the estimated calendar times assume no treatment delays.

    Time frame: After completion of Cycle 1 and Cycle 4 (each cycle is 21 or 28 days, depending on the regimen; approximately 3-4 weeks and 12-16 weeks after treatment initiation, respectively).

Secondary outcomes

  1. Sensitivity of the Multimodal Ultrasound Model for Identifying Hodgkin Lymphoma

    The percentage of participants with histopathologically confirmed Hodgkin lymphoma who are correctly classified as having Hodgkin lymphoma by the multimodal ultrasound model.

    Time frame: At the pretreatment baseline assessment, before initiation of antitumor treatment.

  2. Specificity of the Multimodal Ultrasound Model for Identifying Hodgkin Lymphoma

    The percentage of participants with histopathologically confirmed non-Hodgkin lymphoma who are correctly classified as not having Hodgkin lymphoma by the multimodal ultrasound model.

    Time frame: At the pretreatment baseline assessment, before initiation of antitumor treatment.

  3. Sensitivity of the Multimodal Ultrasound Model for Identifying Aggressive Non-Hodgkin Lymphoma

    The percentage of participants with histopathologically confirmed aggressive non-Hodgkin lymphoma who are correctly classified as having aggressive non-Hodgkin lymphoma by the multimodal ultrasound model.

    Time frame: At the pretreatment baseline assessment, before initiation of antitumor treatment.

  4. Specificity of the Multimodal Ultrasound Model for Identifying Aggressive Non-Hodgkin Lymphoma

    The percentage of participants with histopathologically confirmed indolent non-Hodgkin lymphoma who are correctly classified as not having aggressive non-Hodgkin lymphoma by the multimodal ultrasound model.

    Time frame: At the pretreatment baseline assessment, before initiation of antitumor treatment.

  5. Classification Accuracy of the Multimodal Ultrasound Model for Common Lymphoma Subtypes

    The proportion of participants whose lymphoma subtype is correctly classified by the multimodal ultrasound model, using histopathological diagnosis as the reference standard.

    Time frame: At the pretreatment baseline assessment, before initiation of antitumor treatment.

  6. Correlation Between Multimodal Ultrasound Parameters and Tumor Cell Density

    The association between quantitative multimodal ultrasound parameters and tumor cell density determined by pathological assessment will be evaluated using correlation analysis.

    Time frame: At the pretreatment baseline assessment, using corresponding ultrasound and pathological data.

  7. Correlation Between Multimodal Ultrasound Parameters and Pathological Microvessel Density

    The association between quantitative multimodal ultrasound parameters and microvessel density determined by pathological assessment will be evaluated using correlation analysis.

    Time frame: At the pretreatment baseline assessment, using corresponding ultrasound and pathological data.

  8. Concordance Index of the Multimodal Ultrasound Model for Predicting 2-Year Progression-Free Survival

    The prognostic performance of the multimodal ultrasound model for predicting 2-year progression-free survival (PFS) will be evaluated using the concordance index (C-index). PFS is defined as the time from the date of initial histopathological diagnosis of lymphoma to the first documented disease progression, relapse, or death from any cause, whichever occurs first.

    Time frame: From enrollment to the first documented disease progression or death from any cause, whichever occurs first, assessed through 24 months after enrollment.

  9. Concordance Index of the Multimodal Ultrasound Model for Predicting 2-Year Overall Survival

    The prognostic performance of the multimodal ultrasound model for predicting 2-year overall survival (OS) will be evaluated using the concordance index (C-index). OS is defined as the time from the date of initial histopathological diagnosis of lymphoma to death from any cause.

    Time frame: From enrollment to death from any cause, assessed through 24 months after enrollment.

  10. Comparison of Area Under the Receiver Operating Characteristic Curves Between the Multimodal Ultrasound Model and Radiologists

    The area under the receiver operating characteristic curve (AUC) of the multimodal ultrasound model will be compared with that of radiologists for lymphoma classification, using histopathological diagnosis as the reference standard.

    Time frame: At the pretreatment baseline assessment, before initiation of antitumor treatment.

  11. Incidence of Study Ultrasound-Related Adverse Events

    The number and proportion of participants experiencing adverse events related to study ultrasound examinations, particularly contrast-enhanced ultrasound, will be recorded. Contrast-agent-related adverse events will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Serious adverse reactions will also be documented.

    Time frame: From enrollment through 24 months after enrollment. Record ultrasound-related adverse events throughout follow-up; observe participants for 15-20 minutes after each contrast-enhanced ultrasound examination.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2029, 47 months after the start.

Of 140 non-industry observational studies under Lymphoma, half reached primary completion within 90 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 269. This study's planned 47 months is below that.

Counting every sponsor, half of 159 studies reached it within 82 months; a quarter within 39 and three quarters within 269.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2026
First posted
Nov 17, 2026
StartActual
Jan 1, 2026
Primary completionEst.
Dec 2029
CompletionEst.
Dec 2031
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07941063
Collaborators
National Natural Science Foundation of China
Responsible party
Yu Jie (Chief Physician, Department of Interventional Ultrasound, Chinese PLA General Hospital) — Principal investigator
First posted
Nov 17, 2026
Start date
Jan 1, 2026
Primary completion
Dec 2029 (estimated)
Completion
Dec 2031 (estimated)
Last update
Nov 17, 2026

Study contacts

Jie Yu, PhD
Contact
jiemi301@163.com
01066937110
Jie Yu, PhD
principal investigator · Chinese PLA General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion